JAZZ vs XENE
JAZZ: A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of innovative treatments. XENE: A pre-commercial neuroscience biotech racing to bring azetukalner, a differentiated potassium channel opener, through Phase 3 trials for epilepsy and depression.
Side-by-side fundamentals
| Metric | JAZZ | XENE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $250.41 | $66.18 | |
| Market cap as of 2026-07-23 | $16.0B | $6.7B | |
| P/E as of 2026-07-23 | 543.13 | n/a | |
| PEG as of 2026-07-23 | 58.02 | -0.30 | XENE lower |
| Net margin as of 2026-07-23 | +0.7% | -867.3% | JAZZ higher |
| Gross margin as of 2026-07-23 | +88.0% | n/a | |
| Operating margin as of 2026-07-23 | -0.8% | -969.8% | JAZZ higher |
| ROE as of 2026-07-23 | +0.7% | -49.2% | JAZZ higher |
| ROA as of 2026-07-23 | +0.3% | -46.4% | JAZZ higher |
| Debt / equity as of 2026-07-23 | 1.18 | 0.00 | XENE lower |
| Revenue growth (YoY) as of 2026-07-23 | +9.2% | -7.3% | JAZZ higher |
| Revenue CAGR (3y) SEC XBRL | +5.3% | -77.8% | JAZZ higher |
| Beta as of 2026-07-23 | 0.37 | 0.63 | |
| 1-year return as of 2026-07-22 close | +125.7% | +111.2% | JAZZ higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.